ArticleFrontiers in genetics2026
Identification of key biomarkers of telomere-related genes in diabetic nephropathy via bioinformatic analysis.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic nephropathy (DN) is a major cause of end-stage renal disease. Understanding the molecular mechanisms underlying DN is crucial for developing new therapeutic targets and diagnostic biomarkers. Methods: We utilized microarray data from the GEO database to identify differentially expressed genes related to DN. Machine learning algorithms, including LASSO regression and SVM-RFE, were employed to screen and validate telomere-related genes. We also predicted the transcription factors of the significant genes. Subsequently, correlation analysis and Receiver Operating Characteristic diagnostics were performed on the key genes, along with validation using external datasets. Additionally, GSEA enrichment analysis and immune infiltration analysis were conducted. Furthermore, we analyzed the expression of significant genes in cell subgroups using single-cell sequencing technology. Finally, key genes were validated in DN kidney biopsy tissues and normal kidney biopsy tissues. Results: Through differential analysis and machine learning screening, we identified a total of 14 differentially expressed genes related to telomeres, among which TRIM22, ELOVL4, NLGN4X, and FOSB were highlighted as key genes. We also predicted seven related transcription factors (BCLAF1, HNRNPL, TAF15, STAT1, SRSF9, SAFB2, PTEN). The key gene TRIM22 showed a high correlation with NLGN4X, ELOVL4, and NLGN4X. ROC diagnostics demonstrated sufficient diagnostic accuracy in both the test and validation sets. GSEA enrichment analysis and immune infiltration analysis revealed significant differences among immune cells, such as PC cells, and preliminary expression validation was conducted using single-cell analysis (for example, TRIM22 exhibited high expression levels in EDC, PEC, MES, and IMC). Finally, we performed RT-PCR between DN samples and control samples, finding that the expression levels of key genes in both groups were consistent with the trends predicted by bioinformatics, indicating that these genes may serve as potential diagnostic biomarkers and therapeutic targets. Conclusion: This study provides a comprehensive analysis of telomere-related DEGs in DN, enhancing our understanding of DN pathogenesis. The identified key genes offer potential for new diagnostic and therapeutic strategies, warranting further investigation into their biological roles in DN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.